Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance and category:  

### **Core Concepts & Key Terms**  
- **Anti-D immunoglobulin** (critical for prevention)  
- **Rhesus (Rh) negative** (target population)  
- **Haemolytic disease of the newborn (HDN)** (condition to prevent)  
- **Sensitising events** (triggers for anti-D administration)  

### **Timing & Dosage**  
- **28 weeks gestation** (routine antenatal dose)  
- **Postnatal administration** (if baby is Rh-positive)  
- **Dosage variations**:  
  - **250 IU** (sensitising event <20 weeks)  
  - **500 IU** (sensitising event >20 weeks, postnatal)  
  - **1500 IU** (28 weeks, Intraoperative Cell Salvage [ICS])  
- **Additional anti-D if fetal bleed >4mL** (transfusion consult)  

### **Clinical Events Requiring Anti-D**  
- **Antenatal sensitising events** (e.g., bleeding, trauma, procedures)  
- **Delivery** (mandatory if baby Rh-positive)  
- **Intraoperative Cell Salvage (ICS)** (requires high-dose anti-D)  

### **Testing & Documentation**  
- **Kleihauer test** (assesses fetomaternal hemorrhage)  
- **Booking visit** (initial assessment)  
- **Follow-up procedures** (ensures compliance)  

### **Contraindications & Responsibilities**  
- **Contraindications for anti-D** (e.g., known hypersensitivity)  
- **Midwives/obstetricians** (key implementers)  
- **Management oversight** (ensures protocol accessibility)  

These terms encapsulate the essential clinical, procedural, and administrative aspects of the guideline.